GEN-MKT-18-7897-A
Jun 23, 2017 | Biopharma, Blogs, Pharma | 0 comments
Are you tasked with the bioanalysis of antibody drug conjugates (ADCs)? If so, you know they represent a rapidly growing class of biotherapeutics, but their unique chemical structure makes quantitative analysis particularly challenging.
So, what is the best technique to create a novel quantitative analysis solution that accelerates method development and improves the performance of ADC pharmacokinetic assays?
Typically used Ligand binding assays (LBA) such as Enzyme-Linked Immunosorbent Assays (ELISA) have many advantages. However, LBAs can suffer from high variability, limited dynamic range, and problems with selectivity. An alternative comes with liquid chromatography-tandem mass spectrometry (LC-MS/MS), which has found widespread use in the quantitative analysis of small molecule drugs. While LC-MS/MS assays are exceedingly selective, with excellent dynamic range and reproducibility, they can lack sensitivity when applied to protein therapeutics.
In search of a solution, our experts developed a unique workflow with outstanding results. We combined a universal immunocapture enrichment strategy with sample preparation and a hybrid LBA microflow LC-MS/MS technique and applied it to the total antibody analysis of the ADC of Ado-trastuzumab emtansine in plasma.Read the full report in Chromatography Today >
Some of the highlights:
Read the full article >
This hybrid LBA microflow LC-MS/MS workflow using high capacity streptavidin coated magnetic beads provides a customizable immunocapture strategy that enables the rapid development of high sensitivity pharmacokinetic assays of biotherapeutics during pre-clinical or phase HC studies.
The workflow applies to mAB based therapeutics and results in faster assay development with wide dynamic range, high selectivity, and high sensitivity, with a lower LLOQs than typically achieved by LC-MS/MS using a direct plasma or pellet digest.
Find out how our BioBA Solution can accelerate your biologics bioanalysis >
In today’s environment in which labs are under pressure to reduce operating costs, many will compare the cost of a service contract between third-party providers and the original equipment manufacturer (OEM). At first glance, going with a service contract from a third-party provider may seem like a smart financial move, but experience shows they can introduce risks that affect reliability and compliance.
We recently hosted a webinar focused on streamlining forensic toxicology workflows, featuring expert speakers Maria Sarkisian from the San Francisco Office of the Chief Medical Examiner (SFOCME) and Dr. Dick Paul Kloos from the Netherlands Forensic Institute (NFI). The webinar explored innovative LC-MS/MS strategies that help forensic labs improve efficiency. In this blog, we share highlights from the Q&A session, where our speakers addressed the audience’s questions and shared actionable insights for forensic laboratory professionals.
We’re excited to launch our Ask the PFAS expert series, where we tackle some of the most pressing questions around PFAS testing, containment, and contamination control. In this first instalment, we sit down with Simon Roberts, a SCIEX application scientist, to share practical insights and expert advice.
Posted by
You must be logged in to post a comment.
Share this post with your network